Results 171 to 180 of about 578,337 (355)
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Brian B Liau +19 more
semanticscholar +1 more source
It is revealed that a metabolic–stromal loop driven by oxLDL–OLR1–FOXM1–FGF19 signaling promotes progesterone resistance in endometrial cancer. OxLDL activates epithelial–fibroblast crosstalk, enhancing proliferation and hormonal insensitivity. Disruption of this circuit, especially with resveratrol, restores MPA sensitivity, highlighting a potential ...
Xingchen Li +9 more
wiley +1 more source
ncBAF recognizes the nucleosome through BCL7A in chromatin remodeling. [PDF]
Chen K, Du L, Liu Y, Chen M, Chen Z.
europepmc +1 more source
ARID1A, a SWI/SNF complex component, is frequently mutated in colorectal cancer (CRC). CRC with ARID1A/TP53 concurrent mutations shows marked sensitivity to WEE1 inhibition. ARID1A loss induces R‐loop‐mediated replication stress, impairs ATF3 transcription, and amplifies WEE1i‐induced DNA damage, suggesting a promising therapeutic vulnerability ...
Chi Zhang +17 more
wiley +1 more source
A post‐stroke perivascular niche of microglia characterized by low expression of M2 markers and elevated glycolysis, oxidative phosphorylation (OXPHOS), and phagocytic activity is identified, which is termed stroke‐activated vascular‐associated microglia (stroke‐VAM).
Yanan Li +8 more
wiley +1 more source
Functional interplay between Mediator and RSC/PBAF chromatin remodelling complex in transcription
Kévin M. André
openalex +1 more source
The Cold Signaling Attenuator HIGH EXPRESSION OF OSMOTICALLY RESPONSIVE GENE1 Activates FLOWERING LOCUS C Transcription via Chromatin Remodeling under Short-Term Cold Stress in Arabidopsis [PDF]
Jaehoon Jung +6 more
openalex +1 more source
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia +14 more
wiley +1 more source

